Human Microbiome Market - Major Leaders & Their Global Dominance

The study involved two major activities in estimating the current market size of the human microbiome market. Exhaustive research was conducted to collect information on the market as well as its peer and parent markets.

The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation were used to estimate the market size of segments and subsegments.

The human microbiome field is a rapidly emerging area of biology and offers new routes for personalized healthcare strategies, improved nutrition, animal welfare, and industrial products. Owing to this, the applications of microbiome research are growing at a significant rate.

The human microbiome market is expected to grow from USD 942 million in 2024 to USD 1,731 million by 2027, at a CAGR of 22.5% during 2024–2027.

The major players in the human microbiome market include Enterome Bioscience (France), E.I. du Pont de Nemours and Company (DuPont) (US), 4D Pharma (UK), and Seres Therapeutics (US). Various growth strategies have been adopted by these players, such as product launches, agreements, and acquisitions to increase their presence in the global human microbiome market.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Enterome Bioscience (France) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat microbiome-associated diseases with a focus on IBDs, Crohn’s, and cancer (glioblastoma, colon, pancreatic, lung, and breast) indications. In 2018, the company raised USD 38.5 million (EUR 32 million) in a Series D financing, which will be used for clinical trials of Enterome’s lead development programs, namely, Phase 2 study of the company’s oral FimH blocker EB8018 for the treatment of Crohn’s disease and Phase 1b study of EO2315, a novel immuno-oncology candidate, in patients with aggressive brain cancer (glioblastoma multiforme).

The Major Objectives Behind This Study:

# To define, describe, segment, and forecast the market on the basis of product, application, disease, technology, and region.

# To define, describe, segment, and forecast the human microbiome research spending market on the basis of technology.

# To provide detailed information about the factors influencing market growth (drivers, restraints, opportunities, and challenges).

# To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.

# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.

# To forecast the size of market segments with respect to four main regions (along with countries), namely, North America, Europe, the Asia Pacific (APAC), and the Rest of the World (RoW).

# To profile key players and comprehensively analyze their core competencies in terms of key developments, product portfolios, and financials.

# To track and analyze competitive developments such as acquisitions; partnerships, agreements, & collaborations; product launches; and expansions in the human microbiome market.

Seres Therapeutics (US) is one of the emerging players operating in this market. Its is engaged in developing a range of novel therapeutic products based on the human microbiome. The company’s microbiome therapeutics platform allows to significantly reduce the time typically required to advance therapeutics to the clinic, and ultimately, to the market. The company focuses on R&D to launch advanced products in the market. In 2017, the company invested 278% of its total revenue in R&D activities.

Recent Developments:

# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.

# In 2018, Enterome entered into a co-development and co-promotion agreement with Takeda for its investigational drug candidate EB8018. This drug is used in patients with Crohn's disease and has the potential to expand its use to other gastrointestinal (GI) disorders and liver diseases.

# In  2016, 4D Pharma acquired the production assets of Instituto Biomar to expand its clinical and production capabilities of live biotherapeutics.

Request Sample Pages@ 
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Europe to account for the largest share of the human microbiome market in 2022

On the basis of region, the global human microbiome market is segmented into four major geographies— North America, Europe, the Asia Pacific, and the Rest of the World (RoW). Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this regional segment is mainly due to the high research activity in this region.